These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 10741635

  • 1. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S.
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [Abstract] [Full Text] [Related]

  • 2. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.
    Klinkhardt U, Graff J, Harder S.
    Clin Pharmacol Ther; 2002 Mar; 71(3):176-85. PubMed ID: 11907492
    [Abstract] [Full Text] [Related]

  • 3. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U, Kirchmaier CM, Westrup D, Breddin HK, Mahnel R, Graff J, Hild M, Harder S.
    Thromb Res; 2000 Feb 15; 97(4):201-7. PubMed ID: 10674406
    [Abstract] [Full Text] [Related]

  • 4. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 15; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 15; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 6. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A, Spychalska J, Sitkiewicz D, Zdebska E, Pilichowska I, Piotrowski W, Stepińska J.
    Am J Cardiovasc Drugs; 2007 Jun 15; 7(6):433-9. PubMed ID: 18076210
    [Abstract] [Full Text] [Related]

  • 7. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov 15; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 8. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 15; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 9. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S.
    Clin Pharmacol Ther; 2003 Mar 15; 73(3):232-41. PubMed ID: 12621388
    [Abstract] [Full Text] [Related]

  • 10. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 15; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

  • 11. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM.
    Thromb Haemost; 1998 Feb 15; 79(2):383-8. PubMed ID: 9493595
    [Abstract] [Full Text] [Related]

  • 12. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
    Tetik S, Ak K, Isbir S, Eksioglu-Demiralp E, Arsan S, Iqbal O, Yardimci T.
    Clin Appl Thromb Hemost; 2010 Apr 15; 16(2):189-98. PubMed ID: 19703819
    [Abstract] [Full Text] [Related]

  • 13. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, Szczeklik A.
    Thromb Haemost; 2005 Dec 15; 94(6):1300-5. PubMed ID: 16411409
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar 15; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 16. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T, Ndrepepa G, Kastrati A, Mann JF, Schulz S, Mehilli J, Schömig A.
    Cardiology; 2008 Mar 15; 111(4):247-53. PubMed ID: 18434733
    [Abstract] [Full Text] [Related]

  • 17. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May 15; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 18. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
    Massberg S, Mueller I, Besta F, Thomas P, Gawaz M.
    Am Heart J; 2003 Nov 15; 146(5):E19. PubMed ID: 14597948
    [Abstract] [Full Text] [Related]

  • 19. Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
    Graff J, Harder S.
    Semin Thromb Hemost; 2005 Nov 15; 31(4):482-5. PubMed ID: 16149028
    [Abstract] [Full Text] [Related]

  • 20. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ.
    Clin Appl Thromb Hemost; 1999 Apr 15; 5(2):122-30. PubMed ID: 10725993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.